RaySearch Laboratories AB (publ) will be showcasing the latest oncology software innovations at ASTRO 2022, to be held in San Antonio, October 23-25. Attendees can book demonstrations of RayStation®* treatment planning system, RayCare®* oncology information system, and RayIntelligence®, the cloud-based oncology analytics system, in RaySearch’s booth 3785 during the congress.
The latest versions of RayStation (12A) RayCare (6A) and RayIntelligence (2A) were released in June 2022.
RayStation 12A** brings deep learning segmentation for all users, brachytherapy planning for Elekta afterloaders, as well as numerous enhancements throughout the system, including CyberKnife planning improvements.
RayCare 6A brings multiple improvements to task management, treatment management, and the patient chart, including usability and efficiency upgrades such as user configured templates for selected workspaces. Version 6A also offers improved connectivity with other hospital information systems, allowing users to access information regarding delivered treatment fractions in their preferred system.
RayIntelligence is an innovative cloud-based oncology analytics system which empowers cancer centers to reach new levels of personalized care through insights based on clinical data. The latest version, (2A) provides support for importing DICOM data from other systems, which allows the clinics to pool and analyze data from different sources alongside RayStation data.
Johan Löf, founder and CEO, RaySearch, says: “We are excited to being back on site at ASTRO to meet partners and existing and new customers to showcase the latest innovations with our products. Among other things, we are proud to highlight promising innovations within online adaptive together with our partner Accuray, as well as presenting our new partnerships with Leo Cancer Care and GE HealthCare.”
Partnerships
Accuray
ARTemis1, RaySearch’s and Accuray’s latest joint innovation project within online adaptive, will leverage RayStation’s capability for automated adaptive replanning, RayCare’s powerful clinical workflow management tools and the Accuray ClearRT imaging to facilitate the development of an optimized solution for online adaptive therapy. A joint preview of ARTemis will be showcased by RaySearch and Accuray.
Leo Cancer Care
Together, the combination of RayCare, RayStation and Leo Cancer Care’s solutions will provide a safe, efficient, and fully integrated platform for upright radiation treatments. The technology seeks to improve patient and clinician experience, which will be further solidified by the addition of the well adopted treatment planning solution from RaySearch. Visit the RaySearch (3785) and Leo Cancer Care (4570) booths for more information.
GE HealthCare
GE HealthCare and RaySearch aim to combine RaySearch’s advanced treatment planning system RayStation with GE HealthCare’s leading multi-modality (CT/MR/molecular imaging) simulator systems to make cancer treatment faster and more precise.
Several key advances have also been made together with RaySearch partners IBA, Mevion Medical Systems, Canon Medical Systems, as well as other collaboration partners. Visit the RaySearch booth 3785 to find out more!
RaySearch’s scientific contribution at ASTRO 2022
Poster Presentation: ePoster, number 3294
Session: Poster Q&A 10 - Physics
Title: Implications of Including Tumor Presence Probabilities as Weights in Radiotherapy Optimization
Collaboration: Royal Institute of Technology, KTH
Presenter: Ivar Bengtsson, RaySearch Laboratories (contact person)
Co-author: Albin Fredriksson, RaySearch Laboratories
About RaySearch
RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.
RaySearch software is used by over 800 clinics in more than 40 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.
About RayStation
RayStation®* is a flexible, innovative treatment planning system, chosen by many leading cancer centers worldwide. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, market-leading algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons, and protons, as well as helium and carbon ions. RayStation supports a wide range of treatment machines, providing one control center for all treatment planning needs and ensuring centers get greater value from existing equipment. RayStation also seamlessly integrates with RayCare®*. By harmonizing the treatment planning, the care of cancer patients worldwide is improved.
About RayCare
The RayCare®* oncology information system (OIS) is designed to support the many complex logistical challenges faced by today’s oncology clinics. RayCare is closely integrated with RayStation®* and provides seamless access to all the powerful planning tools in RayStation and RayCommand®. The system efficiently coordinates activities in radiation therapy and offers advanced features for clinical workflow automation, and adaptive radiation therapy. RayCare responds to the demand from clinics for a more user-friendly and workflow-oriented information system that can support the cancer care of the future.
About RayIntelligence
Data-driven oncology represents a new era in healthcare. RayIntelligence® is an innovative cloud-based oncology analytics system that gives meaning to data, empowering cancer centers to reach new levels of personalized care through insights based on clinical data.
* Subject to regulatory clearance in some markets.
** 510(k) is pending under the review of the FDA. Not available for use or sale.
1. Work in progress
For more information, please contact:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com
Björn Hårdemark, interim CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 709 564 217
bjorn.hardemark@raysearchlabs.com